Arcturus Therapeutics Holdings Inc (NAS:ARCT)
$ 17.9 -0.74 (-3.97%) Market Cap: 484.87 Mil Enterprise Value: 297.15 Mil PE Ratio: 0 PB Ratio: 1.85 GF Score: 77/100

Arcturus Therapeutics Holdings Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2023 / 05:00PM GMT
Release Date Price: $17.84 (+2.35%)
Lut Ming Cheng
JPMorgan Chase & Co, Research Division - Research Analyst

Good morning, everyone. Thanks for joining us for another session at the 41st JPMorgan Healthcare Conference. I'm Brian Cheng. I'm the senior biotech analyst here at the firm. Presenting next is Arcturus Therapeutics. We have their CEO, Joe Payne; and also CFO, Andy. I'm going to turn the floor to the Arcturus team and then the presentation will be followed by a Q&A session. Joe, the floor is yours.

Joseph E. Payne
Arcturus Therapeutics Holdings Inc. - Founder, President, CEO & Director

Okay. Thanks, Brian. It's good to be with you. It feels good to come out of a great year and to be able to present and provide an update on what we're doing at Arcturus. Arcturus is a messenger RNA medicines and therapeutics company. We are based in San Diego, headquartered there. We have over 170 employees now. And we're approaching our 10-year anniversary. So 10 years ago, Pad and I started the company with $15,000. So it's an entrepreneurial story.

It's just -- it's been fantastic

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot